Streetbeat News

Analyst Ratings

AVGO

Rosenblatt analyst Hans Mosesmann reiterated a Buy rating on Broadcom (NASDAQ:AVGO) and maintained a $775 price target.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 1:13 pm

VTOL

Benchmark analyst Josh Sullivan reiterated a Buy rating on Bristow Group (NYSE:VTOL) and maintained a $40 price target.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 1:11 pm

TRMR

RBC Capital analyst Matthew Hedberg reiterated an Outperform rating on Tremor Intl (NASDAQ:TRMR) and maintained a $13 price target.

Portfolio Pulse from richadhand@benzinga.com

May 31, 2023 | 1:05 pm

DOCU

DocuSign shares are trading lower after UBS maintained a Sell rating on the stock and lowered its price target from $52 to $45.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 1:05 pm

BLUE

Grizzly Research published a report on bluebird bio, criticizing the company's management and raising concerns about its gene therapy products. The report caused bluebird bio's shares to fall.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 1:04 pm

GMED

Analysts have provided ratings for Globus Medical (NYSE:GMED) within the last quarter, with an average price target of $64.5, implying upside from the current price of $52.61. The current average has decreased by 0.77% from the previous average price target of $65.00.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 1:03 pm

NVRO

In the last quarter, Nevro (NYSE:NVRO) received 3 somewhat bullish, 7 indifferent, and 1 somewhat bearish analyst ratings. The company has an average 12-month price target of $40.64, a 0.47% decrease from the previous average of $40.83.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 1:03 pm

AMLX

Amylyx Pharma (NASDAQ:AMLX) has received 6 bullish and 1 indifferent analyst ratings in the last quarter, with an average 12-month price target of $50.43, up 5.06% from the previous average of $48.00.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 1:02 pm

ALNY

Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock, with an average price target of $270.4, implying an upside from the current price of $186.46. The current average has increased by 34.08% from the previous average price target of $201.67.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 1:01 pm

BOX

In the last quarter, Box (NYSE:BOX) received 3 somewhat bullish and 2 somewhat bearish ratings from analysts. The average 12-month price target for Box is $28.2, a 17.5% increase from the previous average of $24.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 1:01 pm